Latest Dronedarone Stories
Editor Note: For more information about this release, please scroll to bottom. NEW YORK, May 20, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts'
On April 15th 2012, the Financial Times reported that Sanofi’s drug Multaq lost reimbursement in France and faced new restrictions in other countries.
An irregular heartbeat — atrial fibrillation — is a strong predictor of cognitive decline and the loss of independence in daily activities in older people at risk of cardiovascular disease.
LA JOLLA, Calif., June 27, 2011 /PRNewswire/ -- Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announces that the data from its completed Phase 2 CUPID clinical study of MYDICARÂ® for the treatment of advanced heart failure is being published today online in Circulation, an American Heart Association journal.
SEATTLE, Wash., May 23, 2011 /PRNewswire/ -- Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that 18-month data from its Phase 2 CUPID clinical trial of MYDICARÂ® demonstrated continued improvements in clinical outcomes in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.
Two studies to be presented this week address the often-overlooked costs associated with atrial fibrillation (AFib), the most common form of cardiac arrhythmia.
Use of an implanted device to monitor the condition of heart failure patients reduces the rate of hospitalization by 39 percent, according to this study.
- A volcanic mudflow.